JOHN L. ABRUZZO, M.D.
This content is PDF only. Please click on the PDF icon to access.
Meclofenamate sodium (Meclomen; Parke-Davis, Morris Plains, New Jersey), a nonsteroidal anti-inflammatory agent of the fenamate group, has recently been approved by the U.S. Food and Drug Administration for clinical use in rheumatoid arthritis and osteoarthritis. Like the better known drugs in its class—indomethacin (Indocin; Merck Sharp & Dohme, West Point, Pennsylvania), ibuprofen (Motrin; The Upjohn Company, Kalamazoo, Michigan), tolmetin (Tolectin; McNEILAB, Inc., Ft. Washington, Pennsylvania), naproxen (Naprosyn; Syntex Laboratories, Inc., Palo Alto, California), sulindac (Clinoril; Merck & Company, Rahway, New Jersey), and fenoprofen calcium (Nalfon; Eli Lilly & Company, Indianapolis, Indiana)—meclofenamate sodium at its daily recommended dose (300 to 400
ABRUZZO JL. Anti-inflammatory and Antirheumatic Drugs. Ann Intern Med. 1981;94:270–271. doi: https://doi.org/10.7326/0003-4819-94-2-270
Download citation file:
Published: Ann Intern Med. 1981;94(2):270-271.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use